Potent CaV3.1 and CaV3.3 activator. Enhances CaV3.1 and CaV3.3, but not CaV3.2 activity at concentrations of 0.01 - 10 M in neuro2A cells in vitro. Elevates ACh levels in hippocampus. Rescues impaired memory-related behaviors, promotes adult neurogenesis and displays antidepressant-like effects in OBX mice. Orally bioavailable.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 369.41. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.71 mL||13.54 mL||27.07 mL|
|5 mM||0.54 mL||2.71 mL||5.41 mL|
|10 mM||0.27 mL||1.35 mL||2.71 mL|
|50 mM||0.05 mL||0.27 mL||0.54 mL|
References are publications that support the biological activity of the product.
Yabuki et al (2017) Pharmacological properties of SAK3, a novel T-type voltage-gated Ca2+ channel enhancer. Neuropharmacology 117 1 PMID: 28093211
Xu et al (2018) T-type calcium channel enhancer SAK3 produces anti-depressant-like effects by promoting adult hippocampal neurogenesis in olfactory bulbectomized mice. J.Pharmacol.Sci. 137 333 PMID: 30196018
If you know of a relevant reference for SAK 3, please let us know.
View Related Products by Product Action
Keywords: SAK 3, SAK 3 supplier, SAK3, voltage-gated, Ca2+, channels, T-VGCC, memory, orally, bioavailable, CaV3.1, Ca3.3, activators, activates, Voltage-gated, Calcium, Channels, 6239, Tocris Bioscience
Citations for SAK 3
Citations are publications that use Tocris products.
Currently there are no citations for SAK 3. Do you know of a great paper that uses SAK 3 from Tocris? Please let us know.
Reviews for SAK 3
There are currently no reviews for this product. Be the first to review SAK 3 and earn rewards!
Have you used SAK 3?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.